Cambridge, MA, December 18, 2008 – Syndexa Pharmaceuticals Corp., a biopharmaceutical company developing first-in-class drugs to treat metabolic diseases, announced today the appointment of Paul C. Anderson, Ph.D. as Vice President of Medicinal Chemistry.
Dr. Anderson is a synthetic organic chemist by training with more than 23 years of experience in pharmaceutical research and management. He received his Ph.D. in organic chemistry at the University of Alberta. Following postdoctoral studies in bioorganic chemistry at the University of Cambridge, Dr. Anderson began his career in the pharmaceutical industry at Merck Frosst Canada Inc. He subsequently joined Boehringer Ingelheim and in more than 20 years with the company, held positions of increasing responsibility in the research organization including more than 12 years as head of the Boehringer Ingelheim research centers in Canada and in the United States. While in Canada, Dr. Anderson and his team introduced several anti-viral drugs into non-clinical and clinical development, including the first HCV protease inhibitor to be tested in humans. As head of research for Boehringer Ingelheim in the United States, Dr. Anderson and his team carried out research on autoimmune and cardiovascular diseases, advancing several compounds into pre-clinical development.
“We are delighted to have Paul join our management team. Paul brings to our growing team deep medicinal chemistry expertise and a wealth of experience in drug discovery research and organizational development,” said Teo Uysal, President and CEO of Syndexa. “Paul’s talent and leadership will be invaluable to the company. I believe that he is an outstanding addition to the team. I look forward to working with him as we move forward with our discovery programs in metabolic diseases.”
“I am very pleased to have joined Syndexa Pharmaceuticals” said Dr. Anderson. “We have a talented and growing team of scientists working with leading academic labs at the cutting edge of research in metabolic diseases.”
About Syndexa Pharmaceuticals
Syndexa is dedicated to the discovery and development of a new generation of small-molecule drugs targeting the biological interface between inflammatory and metabolic pathways, novel mechanisms for the treatment and prevention of metabolic diseases. Syndexa’s initial targets include endoplasmic reticulum (ER) stress and c-jun N-terminal kinase (JNK). Founded by leading scientists from Harvard and University of California, San Diego, the company has raised over $19M of equity capital to date and is executing on its business strategy to rapidly build and commercialize a portfolio of breakthrough products. The company is headquartered in Cambridge, MA. For additional information, please visit http://www.syndexa.com.
Contact: Teo Uysal, teo.uysal@syndexa.com
